Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

Sinakos, Emmanouil; Dedes, Ioannis; Papalavrentios, Lavrentis; Drevelegas, Antonios; Akriviadis, Evangelos

doi:10.3109/00365521003628335

Cited by 4 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade 3 thrombocytopenia was the only adverse event that appeared to be more frequent with sorafenib-TACE combination therapy than with sorafenib monotherapy, occurring at incidences of 21% and 4% with combination therapy and monotherapy, respectively. One study that investigated combination treatment with sorafenib and TACE for treating HCC (n ϭ 14) reported a mean duration of the combined treatment of 12 months without any grade 3 or 4 adverse events [21]. However, that was a retrospective analysis in which sorafenib treatment was administered several months after the first session of TACE.…”

Section: Discussionmentioning

confidence: 99%

Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study

et al. 2010

View full text Add to dashboard Cite

Background and Aim. It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. This study assesses the safety and tolerability of a continuous regimen of sorafenib combined with TACE.Methods. This was an open-label phase I study testing a continuous administration of sorafenib (dose escalation from 200 mg twice daily [bid] to 400 mg bid) starting 7 days prior to TACE with doxorubicin (50 mg).Results. Twenty-one patients were screened and 14 received sorafenib combined with TACE. Because there were no dose-limiting toxicities in the first three patients who received sorafenib at a dose of 200 mg bid, subsequent patients received 400 mg bid. Twenty-seven procedures were performed (median, two per patient) and two local therapy-related severe adverse events occurred. The median duration of sorafenib therapy was

show abstract

Section: Discussionmentioning

confidence: 99%

Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study

et al. 2010

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science

Weintraub

Salem

2013

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

Cited by 4 publications

References 10 publications

Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study

Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study

Current awareness: Pharmacoepidemiology and drug safety

Treatment of Hepatocellular Carcinoma Combining Sorafenib and Transarterial Locoregional Therapy: State of the Science

Contact Info

Product

Resources

About